• CAEL-101 is well tolerated in patients with AL amyloidosis.

  • CAEL-101 leads to rapid and sustained organ responses in patients with AL amyloidosis previously treated with standard therapy.

Systemic immunoglobulin light-chain amyloidosis is characterized by pathologic deposition of immunoglobulin light chains as amyloid fibrils in vital organs, leading to organ impairment and eventual death. That the process is reversible was evidenced in an in vivo experimental model in which fibril-reactive chimeric monoclonal antibody (mAb) 11-1F4 directly targeted human light-chain amyloid deposits and affected their removal via a phagocyte-mediated response. To determine the tolerability and potential amyloidolytic effect of this agent (now designated mAb CAEL-101), we conducted a phase 1a/b study involving 27 patients, most of whom had manifestations of organ involvement. This was an open-label study in which phase 1a patients received mAb CAEL-101 as a single intravenous infusion with escalating dose levels from 0.5 mg/m2 to 500 mg/m2 to establish the maximum tolerated dose (MTD). In phase 1b, the antibody was administered as a graded series of 4 weekly infusions. For both phases, there were no drug-related serious adverse events or dose-limiting toxicities among recipients, and the MTD was not reached. The majority of patients had deep hematologic responses but persistent organ disease prior to treatment. Fifteen of 24 patients (63%) who manifested cardiac, renal, hepatic, gastrointestinal, or soft tissue involvement had a therapeutic response to mAb CAEL-101 as evidenced by serum biomarkers or objective imaging modalities with a median time to response of 3 weeks. Infusions of mAb CAEL-101 were well tolerated and, for the majority, resulted in improved organ function, notably for those with cardiac impairment. This trial was registered at www.clinicaltrials.gov as #NCT02245867.

1.
Rosenzweig
M
,
Giralt
S
,
Landau
H
.
Light-chain amyloidosis: SCT, novel agents and beyond
.
Bone Marrow Transplant.
2012
;
48
(
8
):
1022
-
1027
.
2.
Merlini
G
,
Wechalekar
AD
,
Palladini
G
.
Systemic light chain amyloidosis: an update for treating physicians
.
Blood.
2013
;
121
(
26
):
5124
-
5130
.
3.
Gertz
MA
.
Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management
.
Am J Hematol.
2011
;
86
(
2
):
180
-
186
.
4.
Kumar
S
,
Dispenzieri
A
,
Lacy
MQ
, et al
.
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
.
J Clin Oncol.
2012
;
30
(
9
):
989
-
995
.
5.
Cohen
A
,
Comenzo
R
.
Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy
Hematology Am Soc Hematol Educ Program. 2010;2010:287-294.
6.
Gertz
MA
,
Lacy
MQ
,
Dispenzieri
A
, et al
.
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report
.
Leuk Lymphoma.
2010
;
51
(
12
):
2181
-
2187
.
7.
Sanchorawala
V
,
Sarosiek
S
,
Schulman
A
, et al
.
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study
.
Blood.
2020
;
135
(
18
):
1541
-
1547
.
8.
Roussel
M
,
Merlini
G
,
Chevret
S
, et al
.
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis
.
Blood.
2020
;
135
(
18
):
1531
-
1540
.
9.
Kimmich
CR
,
Terzer
T
,
Benner
A
, et al
.
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria
.
Blood.
2020
;
135
(
18
):
1517
-
1530
.
10.
Kastritis
E
,
Palladini
G
,
Minnema
MC
, et al;
ANDROMEDA Trial Investigators
.
Daratumumab-based treatment for immunoglobulin light-chain amyloidosis
.
N Engl J Med.
2021
;
385
(
1
):
46
-
58
.
11.
Muchtar
E
,
Gertz
MA
,
Kumar
SK
, et al
.
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
.
Blood.
2017
;
129
(
15
):
2111
-
2119
.
12.
Mahmood
S
,
Palladini
G
,
Sanchorawala
V
,
Wechalekar
A
.
Update on treatment of light chain amyloidosis
.
Haematologica.
2014
;
99
(
2
):
209
-
221
.
13.
O’Nuallain
B
,
Allen
A
,
Kennel
SJ
,
Weiss
DT
,
Solomon
A
,
Wall
JS
.
Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains
.
Biochemistry.
2007
;
46
(
5
):
1240
-
1247
.
14.
Hrncic
R
,
Wall
J
,
Wolfenbarger
DA
, et al
.
Antibody-mediated resolution of light chain-associated amyloid deposits
.
Am J Pathol.
2000
;
157
(
4
):
1239
-
1246
.
15.
Solomon
A
,
Weiss
DT
,
Wall
JS
.
Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4
.
Clin Cancer Res.
2003
;
9
(
10 Pt 2
):
3831S
-
3838S
.
16.
Wall
JS
,
Kennel
SJ
,
Stuckey
AC
, et al
.
Radioimmunodetection of amyloid deposits in patients with AL amyloidosis
.
Blood.
2010
;
116
(
13
):
2241
-
2244
.
17.
Palladini
G
,
Dispenzieri
A
,
Gertz
MA
, et al
.
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes
.
J Clin Oncol.
2012
;
30
(
36
):
4541
-
4549
.
18.
Palladini
G
,
Hegenbart
U
,
Milani
P
, et al
.
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
.
Blood.
2014
;
124
(
15
):
2325
-
2332
.
19.
Gertz
MA
,
Comenzo
R
,
Falk
RH
, et al
.
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004
.
Am J Hematol.
2005
;
79
(
4
):
319
-
328
.
20.
Kaufman
GP
,
Dispenzieri
A
,
Gertz
M
et al
.
Kinetics of Organ Response and Survival following Normalization of the Serum Free Light Chain Ratio in AL Amyloidosis
. November 12,
2014
.
21.
Muchtar
E
,
Dispenzieri
A
,
Leung
N
, et al
.
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria
.
Leukemia.
2018
;
32
(
10
):
2240
-
2249
.
22.
Buss
SJ
,
Emami
M
,
Mereles
D
, et al
.
Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers
.
JACC Cardiovas Imaging.
2012
;
60
(
12
):
1067
-
1076
.
23.
B
ellavia
D
,
Pellikka
PA
,
Al-Zahrani
GB
, et al
.
Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study
.
J Am Soc Echocardiogr.
2010
;
23
(
6
):
643
-
652
.
24.
Koyama
J
,
Falk
RH
.
Prognostic significance of strain Doppler imaging in light-chain amyloidosis
.
JACC Cardiovasc Imaging.
2010
;
3
(
4
):
333
-
342
.
25.
Richards
DB
,
Cookson
LM
,
Berges
AC
, et al
.
Therapeutic clearance of amyloid by antibodies to serum amyloid P component
.
N Engl J Med.
2015
;
373
(
12
):
1106
-
1114
.
26.
W
all
JS
,
Kennel
SJ
,
Richey
T
, et al
.
Generation and characterization of anti-AA amyloid-specific monoclonal antibodies
.
Front Immunol.
2011
;
2
:
32
.
27.
Wall
JS
,
Kennel
SJ
,
Williams
A
, et al
.
AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils
.
PLoS One.
2012
;
7
(
12
):
e52686
.
28.
Gertz
MA
,
Landau
H
,
Comenzo
RL
, et al
.
First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction
.
J Clin Oncol.
2016
;
34
(
10
):
1097
-
1103
.
29.
Prothena. Prothena discontinues development of NEOD001 for AL amyloidosis. http://ir.prothena.com/news-releases/news-release-details/prothena-discontinues-development-neod001-al-amyloidosis?releaseid=1064584. Accessed 10 September 2020.
You do not currently have access to this content.

Sign in via your Institution